Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Ruboxistaurin hydrochloride

SKU: orb1225962

Description

A potent, selective, ATP-competitive, orally available PKC beta (PKCβ) inhibitor with IC50 of 4.7 and 5.9 nM for PKCβ I and PKCβ II, respectively; displays >60-fold selectivity over PKCα, and other ATP dependent kinases (PKA, Calcium calmodulin, Caesin kinase and Src); ameliorates the glomerular filtration rate, albumin excretion rate, and retinal circulation in diabetic rats.Heart Failure Phase 2 Discontinued.

Research Area

Pharmacology & Drug Discovery

Images & Validation

Key Properties

CAS Number169939-93-9
MW505.0079
Purity>98% (HPLC)
FormulaC28H29ClN4O3
SMILESCN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O.Cl
TargetPKC
SolubilityDMSO: 6.8 mg/mL (Need ultrasonic and warming)

Bioactivity

In Vivo
Ruboxistaurin (1 mg/kg; 8 weeks) markedly reduces GEC apoptosis as well as swiprosin-1 upregulation, and ameliorates renal glomerular injury in the diabetic mice. Ruboxistaurin also potently attenuates the expression of PARP, cleaved-caspase9, cleaved-caspase3, and the Bax/Bcl-2 ratio, in diabetic mice. Ruboxistaurin (0.1, 1.0, or 10.0 mg/kg; p.o.) dramatically reduces the number of leukocytes trapped in the retinal microcirculation of diabetic rats.
In Vitro
Ruboxistaurin hydrochloride is a selective and ATP-competitive PKCβ inhibitor, with IC50s of 4.7 and 5.9 nM for PKCβI and PKCβII, shows less potent inhibition on PKCη (IC50, 52 nM), PKCα (IC50, 360 nM), PKCγ (IC50, 300 nM), PKCδ (IC50, 250 nM), and has no effect on PKCζ (IC50, >100 μM). Ruboxistaurin (10 and 400 nM) dramatically inhibits glucose-induced monocyte adherence to levels that are not different from baseline adherence of monocytes to endothelial cells under NG conditions. Ruboxistaurin (10 and 400 nM) dose not alter the endothelial expression of adhesion molecules or modify endothelial cell growth. Ruboxistaurin (LY333531; 10 nM) reduces high-glucose (HG)-induced human renal glomerular endothelial cells (HRGECs) viability, and inhibits the increases in swiprosin-1 in HRGECs incubated with HG.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

LY333531 hydrochloride | LY-333531 hydrochloride

Similar Products

  • Ruboxistaurin hydrochloride [orb1693357]

    95.97% (May vary between batches)

    169939-93-9

    505.01

    C28H28N4O3·HCl

    1 ml x 10 mM (in DMSO), 100 mg, 500 mg, 2 mg, 5 mg, 1 mg, 10 mg, 25 mg, 50 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Ruboxistaurin hydrochloride (orb1225962)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

5 mg
$ 260.00
10 mg
$ 430.00
25 mg
$ 840.00
50 mg
$ 1,210.00
100 mg
$ 1,680.00
500 mg
$ 3,340.00